Accelerate Diagnostics, Inc. (AXDX) Analysts See $-0.33 EPS

February 20, 2018 - By Marguerite Chambers

 Accelerate Diagnostics, Inc. (AXDX) Analysts See $ 0.33 EPS
Investors sentiment decreased to 1.63 in 2017 Q3. Its down 1.37, from 3 in 2017Q2. It dived, as 15 investors sold Accelerate Diagnostics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 38 raised stakes. 21.32 million shares or 11.33% more from 19.15 million shares in 2017Q2 were reported.
Chartist Ca has 64,765 shares for 0.68% of their portfolio. Blackrock holds 0% or 1.67 million shares. Barbara Oil invested in 9,000 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys has invested 0.02% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Cannell Peter B Inc reported 1.10M shares. Miura Glob Mngmt Limited Com invested in 960,000 shares or 5.62% of the stock. First Trust Advsr L P stated it has 88,795 shares. Driehaus Mngmt Ltd Com stated it has 39,714 shares. State Street Corporation accumulated 484,210 shares. Credit Suisse Ag invested in 1.82M shares. Alliancebernstein Limited Partnership reported 0% stake. Bankshares Of America Corporation De, a North Carolina-based fund reported 8,820 shares. First Republic Inv Mgmt accumulated 668,600 shares or 0.11% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 956 shares. Tiaa Cref Management Lc has invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

Since August 21, 2017, it had 5 insider purchases, and 0 insider sales for $9.01 million activity.

Analysts expect Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report $-0.33 EPS on February, 26.They anticipate $0.02 EPS change or 6.45 % from last quarter’s $-0.31 EPS. After having $-0.31 EPS previously, Accelerate Diagnostics, Inc.’s analysts see 6.45 % EPS growth. The stock increased 1.00% or $0.25 during the last trading session, reaching $25.15. About 406,710 shares traded or 1.55% up from the average. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has risen 147.12% since February 20, 2017 and is uptrending. It has outperformed by 130.42% the S&P500.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Coverage

Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Accelerate Diagnostics had 9 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has “Buy” rating given on Sunday, September 17 by Piper Jaffray. The firm has “Overweight” rating by JP Morgan given on Tuesday, August 9. BTIG Research reinitiated Accelerate Diagnostics, Inc. (NASDAQ:AXDX) rating on Wednesday, July 12. BTIG Research has “Buy” rating and $3400 target. The company was initiated on Friday, January 8 by William Blair. The rating was downgraded by BTIG Research to “Neutral” on Wednesday, December 13. BTIG Research upgraded the stock to “Neutral” rating in Tuesday, August 25 report. JP Morgan initiated the stock with “Overweight” rating in Thursday, March 24 report. The firm earned “Overweight” rating on Wednesday, December 16 by Piper Jaffray. The rating was maintained by Piper Jaffray with “Buy” on Thursday, August 3.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.40 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

More notable recent Accelerate Diagnostics, Inc. (NASDAQ:AXDX) news were published by: which released: “Accelerate Diagnostics Rides High On Innovative Product Launches In 2017” on June 05, 2017, also with their article: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q4 2017 Results …” published on February 16, 2018, published: “Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher” on November 16, 2017. More interesting news about Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released by: and their article: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q3 2017 Results …” published on November 05, 2017 as well as‘s news article titled: “Accelerate Diagnostics Reports Q2 2017 Financial Results, Doubles Revenue …” with publication date: August 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.